OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
Tobias Puengel, Frank Tacke
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1249-1263
Open Access | Times Cited: 8
Tobias Puengel, Frank Tacke
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1249-1263
Open Access | Times Cited: 8
Showing 8 citing articles:
Pharmacological treatment options for metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes mellitus: A systematic review
L Konings, Lorena Miguelañez‐Matute, Anna M P Boeren, et al.
European Journal of Clinical Investigation (2025)
Open Access | Times Cited: 1
L Konings, Lorena Miguelañez‐Matute, Anna M P Boeren, et al.
European Journal of Clinical Investigation (2025)
Open Access | Times Cited: 1
Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications
Farah Abdelhameed, A.I. Mustafa, Chris Kite, et al.
Livers (2025) Vol. 5, Iss. 1, pp. 11-11
Open Access
Farah Abdelhameed, A.I. Mustafa, Chris Kite, et al.
Livers (2025) Vol. 5, Iss. 1, pp. 11-11
Open Access
Mannose reduces fructose metabolism and reverses MASH in human liver slices and murine models in vivo
John G. Hong, Joshaya C. Trotman, Yvette Carbajal, et al.
Hepatology Communications (2025) Vol. 9, Iss. 4
Open Access
John G. Hong, Joshaya C. Trotman, Yvette Carbajal, et al.
Hepatology Communications (2025) Vol. 9, Iss. 4
Open Access
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease
Bryan Adrian Priego‐Parra, Rocío Gallego‐Durán, Berenice M Román-Calleja, et al.
Trends in Endocrinology and Metabolism (2025)
Closed Access
Bryan Adrian Priego‐Parra, Rocío Gallego‐Durán, Berenice M Román-Calleja, et al.
Trends in Endocrinology and Metabolism (2025)
Closed Access
Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction‐associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta‐analysis
Jiaxin Zhong, Zixin Cai, Guanghui Zhu, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Jiaxin Zhong, Zixin Cai, Guanghui Zhu, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Sea buckthorn triterpenic acids alleviates metabolic dysfunction-associated steatotic liver disease via modulation of liver biochemistry, lipid metabolism and AMPK/Nrf2/NF-κB signaling pathway
Lichengcheng Ren, Yongjing Xie, Ruinan Wang, et al.
Food Bioscience (2025), pp. 106611-106611
Closed Access
Lichengcheng Ren, Yongjing Xie, Ruinan Wang, et al.
Food Bioscience (2025), pp. 106611-106611
Closed Access
Cell-specific regulation of insulin action and hepatic fibrosis by CEACAM1
Basel Aldroubi, John Najjar, Tya S Youssef, et al.
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 4
Open Access | Times Cited: 1
Basel Aldroubi, John Najjar, Tya S Youssef, et al.
Metabolism and Target Organ Damage (2024) Vol. 4, Iss. 4
Open Access | Times Cited: 1
Dawn of an era of effective treatments for MAFLD
Cameron Gofton, George Casella
Portal hypertension & cirrhosis (2024)
Open Access
Cameron Gofton, George Casella
Portal hypertension & cirrhosis (2024)
Open Access
